Paul Oh, PhD

Dr. Oh, a Ph.D. graduate from Harvard Medical School, has significantly advanced HHT research. His postdoctoral training at Mass General Hospital was instrumental in establishing genetically engineered mouse models of HHT. At the University of Florida, he developed HHT models with clinical features, utilizing Acvrl1, Eng, and Smad4 conditional knockout lines. Dr. Oh is recognized for pioneering real-time imaging techniques that continuously monitor AVM development and progression in these models. Since transferring to Barrow Neurological Institute in 2017, he has continued his research on HHT and brain AVMs. He recently identified Bmp10 as the critical physiological ligand in ENG-ALK1 signaling, offering key insights into HHT pathogenesis. Dedicated to patient benefit, Dr. Oh collaborates with pharmaceutical companies to test novel therapeutic drugs in preclinical HHT models. He actively supports the HHT community through leadership roles in CureHHT committees and international HHT conferences.